Literature DB >> 7735171

No-carrier-added meta-[123I]iodobenzylguanidine: synthesis and preliminary evaluation.

G Vaidyanathan1, M R Zalutsky.   

Abstract

No-carrier-added [123I]MIBG was prepared from 3-(trimethylsilyl)benzylguanidine in 80-90% yield. Binding of this tracer to SK-N-SH human neuroblastoma cells maintained a constant level of > 50% over 2-3 log activity range. In comparison, the binding of [123I]MIBG prepared by isotopic exchange steadily decreased with dose. Biodistribution studies in normal mice demonstrated maximal concentrations in heart and adrenals for both preparations. In heart, significant 1.5-3.0 times higher levels (P < 0.05) were seen for the no-carrier-added preparation. Radiation dosimetry calculations suggest that the no-carrier-added preparation would increase the dose received by several tissues, most notably the heart where a 91% increase in dose is predicted.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7735171     DOI： 10.1016/0969-8051(94)00078-x

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN： 0969-8051            Impact factor:   2.408


  7 in total

1.  Synthesis and evaluation of 18F-labeled benzylguanidine analogs for targeting the human norepinephrine transporter.

Authors:  Hanwen Zhang; Ruimin Huang; NagaVaraKishore Pillarsetty; Daniel L J Thorek; Ganesan Vaidyanathan; Inna Serganova; Ronald G Blasberg; Jason S Lewis
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-10-31       Impact factor: 9.236

2.  No-carrier-added versus carrier-added123I-metaiodobenzylguanidine for the assessment of cardiac sympathetic nerve activity.

Authors:  Hein J Verberne; Kora de Bruin; Jan B A Habraken; G Aernout Somsen; Jos L H Eersels; Frits Moet; Jan Booij; Berthe L F van Eck-Smit
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-01-20       Impact factor: 9.236

3.  Radiation dose estimation using preclinical imaging with 124I-metaiodobenzylguanidine (MIBG) PET.

Authors:  Chang-Lae Lee; Hilla Wahnishe; George A Sayre; Hyo-Min Cho; Hee-Joung Kim; Miguel Hernandez-Pampaloni; Randall A Hawkins; Shorouk F Dannoon; Henry F VanBrocklin; Melissa Itsara; William A Weiss; Xiaodong Yang; Daphne A Haas-Kogan; Katherine K Matthay; Youngho Seo
Journal:  Med Phys       Date:  2010-09       Impact factor: 4.071

Review 4.  Norepinephrine Transporter as a Target for Imaging and Therapy.

Authors:  Neeta Pandit-Taskar; Shakeel Modak
Journal:  J Nucl Med       Date:  2017-09       Impact factor: 10.057

5.  Clinical performance and radiation dosimetry of no-carrier-added vs carrier-added 123I-metaiodobenzylguanidine (MIBG) for the assessment of cardiac sympathetic nerve activity.

Authors:  Hein J Verberne; Ellinor Busemann Sokole; Astrid F van Moerkerken; Joop H W M Deeterink; Geert Ensing; Michael G Stabin; G Aernout Somsen; Berthe L F van Eck-Smit
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-01-04       Impact factor: 9.236

Review 6.  Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle.

Authors:  Yana Dekempeneer; Marleen Keyaerts; Ahmet Krasniqi; Janik Puttemans; Serge Muyldermans; Tony Lahoutte; Matthias D'huyvetter; Nick Devoogdt
Journal:  Expert Opin Biol Ther       Date:  2016-05-19       Impact factor: 4.388

7.  Localisation of [131I]MIBG in nude mice bearing SK-N-SH human neuroblastoma xenografts: effect of specific activity.

Authors:  G Vaidyanathan; H S Friedman; S T Keir; M R Zalutsky
Journal:  Br J Cancer       Date:  1996-05       Impact factor: 7.640
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.